Antinociception Induced by Copper Salt Revisited: Interaction with Ketamine in Formalin-Induced Intraplantar and Orofacial Pain in Mice

Aims: To evaluate in mice the antinociceptive effect of copper in spinal and trigeminal nociceptive pathways by using the intraplantar and orofacial formalin tests, respectively, and to examine whether this effect may interact synergistically with ketamine-induced antinociception. Methods: Nociceptive behaviors (licking/biting of the formalin-injected limb and rubbing/scratching of the formalin-injected orofacial area) in male mice were evaluated during a 45-minute observation period post–formalin injection. Dose-response curves for intraperitoneal (ip) copper sulfate and ketamine allowed their combination in equi-effective doses, and their interaction was determined with isobolographic analysis. The results were examined with one-way analysis of variance followed by the Bonferroni post hoc test. Significance was accepted at an alpha level of .05. Results: Irrespective of the region injected with formalin (upper lip or hindlimb), copper sulfate (0.3, 1.0, and 3.0 mg/kg) and ketamine (1.0, 3.0, and 10 mg/kg) dose-dependently decreased the nociceptive behaviors evoked by formalin injection. Isobolographic analysis showed a superadditive interaction between copper and ketamine at the spinal level, but this interaction was only additive at the trigeminal level. Conclusion: The results suggest that copper salts could be used to synergistically improve the efficacy of some commercial centrally acting analgesic agents, such as ketamine, while reducing the possibility of side effects. However, a synergistic effect probably should not be expected if treatment is for orofacial pain.

copper, intraplantar formalin;isobologram, ketamine;orofacial formalin

1.World Health Organization. Trace Elements in Human Nutrition and Health. Geneva, Switzerland: World Health Organization, 1996.

2.Turnlund JR, Keyes WR, Peiffer GL, Scott KC. Copper ab-sorption, excretion, and retention by young men consuming low dietary copper determined by using the stable isotope 65Cu. Am J Clin Nutr 1998;67:1219–1225.

3.Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treat-ment of Wilson’s disease. J. Neural Transm (Vienna) 2000; 107:321–329.

4.Kardos J, Kovács I, Hajós F, Kálmán M, Simonyi M. Nerve end-ings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neurosci Lett 1989;103:139–144.

5.Doreulee N, Yanovsky Y, Haas HL. Suppression of long-term potentiation in hippocampal slices by copper. Hippocampus 1997;7:666–669.

6.Salazar-Weber NL, Smith JP. Copper inhibits NMDA recep-tor-independent LTP and modulates the paired-pulse ratio after LTP in mouse hippocampal slices. Int J Alzheimers Dis 2011;2011:864753.

7.Kapkaeva MR, Popova OV, Kondratenko RV, et al. Effects of copper on viability and functional properties of hippocampal neurons in vitro. Exp Toxicol Pathol 2017;69:259–264.

8.Coddou C, Villalobos C, González J, Acuña-Castillo C, Loeb B, Huidobro-Toro JP. Formation of carnosine-Cu(II) complexes prevents and reverts the inhibitory action of copper in P2X4 and P2X7 receptors. J Neurochem 2002;80:626–633.

9.Coddou C, Morales B, Huidobro-Toro JP. Neuromodulator role of zinc and copper during prolonged ATP applications to P2X4 purinoceptors. Eur J Pharmacol 2003;472:49–56.

10.Vlachová V, Zemková H, Vyklický L Jr. Copper modulation of NMDA responses in mouse and rat cultured hippocampal neu-rons. Eur J Neurosci 1996;8:2257–2264.

11.Weiser T, Wienrich M. The effects of copper ions on glutamate receptors in cultured rat cortical neurons. Brain Res 1996; 742:211–218.

12.Horning MS, Trombley PQ. Zinc and copper influence excit-ability of rat olfactory bulb neurons by multiple mechanisms. J Neurophysiol 2001;86:1652–1660.

13.Aedo F, Delgado R, Wolff D, Vergara C. Copper and zinc as modulators of neuronal excitability in a physiologically signifi-cant concentration range. Neurochem Int 2007;50:591–600.

14.Mathie A, Sutton GL, Clarke CE, Veale EL. Zinc and copper: Pharmacological probes and endogenous modulators of neu-ronal excitability. Pharmacol Ther 2006;111:567–583.

15.Okuyama S, Hashimoto S, Aihara H, Willingham WM, Sorenson JR. Copper complexes of nonsteroidal antiinflam-matory agents: Analgesic activity and possible opioid receptor activation. Agents Actions 1987;21:130–144.

16.Tamba BI, Leon MM, Petreus T. Common trace elements al-leviate pain in an experimental mouse model. J Neurosci Res 2013;91:554–561.

17.Gumilar F, Agotegaray M, Bras C, Gandini NA, Minetti A, Quinzani O. Anti-nociceptive activity and toxicity evaluation of Cu(II)-fenoprofenate complexes in mice. Eur J Pharmacol 2012;675:32–39.

18.El-Gammal OA, Elmorsy EA, Sherif YE. Evaluation of the an-ti-inflammatory and analgesic effects of Cu(II) and Zn(II) com-plexes derived from 2-(naphthalen-1-yloxy)-N’-(1-(pyridine-2-1) ethylidene) acetohydrazide. Spectrochim Acta A Mol Biomol Spectrosc 2014;120:332–339.

19.Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis. Boca Raton: Chapman & Hall, 2000.

20.Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006;319:1–7.

21.Tawfic QA. A review of the use of ketamine in pain manage-ment. J Opioid Manag 2013;9:379–388.

22 Niesters M, Martini C, Dahan A. Ketamine for chronic pain: Risks and benefits. Br J Clin Pharmacol 2014;77:357–367.

23.National Research Council. Guide for the Care and Use of Laboratory Animals, ed 8. Washington D.C.: National Academy, 2011.

24.Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–191.

25.Zhao CS, Tao YX, Tall JM, Donovan DM, Meyer RA, Raja SN. Role of micro-opioid receptors in formalin-induced pain be-havior in mice. Exp Neurol 2003;184:839–845.

26.Luccarini P, Childeric A, Gaydier AM, Voisin D, Dallel R. The orofacial formalin test in the mouse: A behavioral model for studying physiology and modulation of trigeminal nociception. J Pain 2006;7:908–914.

27.Desroches J, Bouchard JF, Gendron L, Beaulieu P. Involvement of cannabinoid receptors in peripheral and spinal morphine an-algesia. Neuroscience 2014;261:23–42.

28.Katsuyama S, Otowa A, Kamio S, et al. Effect of plantar sub-cutaneous administration of bergamot essential oil and linalool on formalin-induced nociceptive behavior in mice. Biomed Res 2015;36:47–54.

29.Gonzalez C, Zegpi C, Noriega V, Prieto JC, Miranda HF. Synergism between dexketoprofen and meloxicam in an oro-facial formalin test was not modified by opioid antagonists. Pharmacol Rep 2011;63:433–440.

30.Miyamoto M, Tsuboi Y, Honda K, et al. Involvement of AMPA receptor GluR2 and GluR3 trafficking in trigeminal spinal sub-nucleus caudalis and C1/C2 neurons in acute-facial inflamma-tory pain. PLoS One 2012;7:e44055.

31.Tallarida RJ. Drug combinations: Tests and analysis with isoboles. Curr Protoc Pharmacol 2016;72:9.19.1–9.19.19.

32.Agotegaray M, Gumilar F, Boeris M, Toso R, Minetti A. Enhanced analgesic properties and reduced ulcerogenic effect of a mononuclear copper(II) complex with fenoprofen in comparison to the parent drug: Promising insights in the treatment of chron-ic inflammatory diseases. Biomed Res Int 2014;2014:505987.

33.Chizh BA. Low dose ketamine: A therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plas-ticity in pain pathways. J Psychopharmacol 2007;21:259–271.

34.Persson J. Ketamine in pain management. CNS Neurosci Ther 2013;19:396–402.

35.Honey CR, Miljkovic Z, MacDonald JF. Ketamine and phen-cyclidine cause a voltage-dependent block of responses to L- aspartic acid. Neurosci Lett 1985;61:135–139.

36.MacDonald JF, Bartlett MC, Mody I, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 1991;432: 483–508.

37.Pelissier T, Infante C, Constandil L, Espinosa J, Lapeyra CD, Hernández A. Antinociceptive effect and interaction of uncom-petitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthrit-ic rats. Pain 2008;134:113–127.

38.Popa MO, Lerche H. Cu2+ (1,10 phenanthroline)3 is an open-channel blocker of the human skeletal muscle sodium channel. Br J Pharmacol 2006;147:808–814.

39.Narahashi T, Ma JY, Arakawa O, Reuveny E, Nakahiro M. GABA receptor-channel complex as a target site of mercury, copper, zinc, and lanthanides. Cell Mol Neurobiol 1994;14:599–621.

40.Trombley PQ, Horning MS, Blakemore LJ. Carnosine modu-lates zinc and copper effects on amino acid receptors and syn-aptic transmission. Neuroreport 1998;9:3503–3507.

41.Bereiter DA, Hirata H, Hu JW. Trigeminal subnucleus cau-dalis: Beyond homologies with the spinal dorsal horn. Pain 2000;88:221–224.

42.Ren K, Dubner R. The role of trigeminal interpolaris-caudalis transition zone in persistent orofacial pain. Int Rev Neurobiol 2011;97:207–225.

43.Aicher SA, Hermes SM, Whittier KL, Hegarty DM. Descending projections from the rostral ventromedial medulla (RVM) to tri-geminal and spinal dorsal horns are morphologically and neu-rochemically distinct. J Chem Neuroanat 2012;43:103–111.

44.Connor M. What would 5-HT do? Regional diversity of 5-HT(1) receptor modulation of primary afferent neurotransmission. Br J Pharmacol 2012;167:353–355.

45.Cumberbatch MJ, Hill RG, Hargreaves RJ. Differential ef-fects of the 5HT1B/1D receptor agonist naratriptan on tri-geminal versus spinal nociceptive responses. Cephalalgia 1998;18:659–663.

46.Hargreaves KM. Orofacial pain. Pain 2011;152(suppl):s25–s32.

47.Xie YF, Jiang XH, Sessle BJ, Yu XM. Development of regional specificity of spinal and medullary dorsal horn neurons. World J Biol Chem 2016;7:138–145.

48.McNamara CR, Mandel-Brehm J, Bautista DM, et al. TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci U S A 2007;104:13525–13530.

49.Dallel R, Raboisson P, Clavelou P, Saade M, Woda A. Evidence for a peripheral origin of the tonic nociceptive response to sub-cutaneous formalin. Pain 1995;61:11–16.

50.Chen Y, Kanju P, Fang Q, et al. TRPV4 is necessary for trigem-inal irritant pain and functions as a cellular formalin receptor. Pain 2014;155:2662–2672.

51.Vandewauw I, Owsianik G, Voets T. Systematic and quantita-tive mRNA expression analysis of TRP channel genes at the single trigeminal and dorsal root ganglion level in mouse. BMC Neurosci 2013;14:21.

52.Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008;49:2059–2080.

53.Galhardi CM, Diniz YS, Faine LA, et al. Toxicity of copper in-take: Lipid profile, oxidative stress and susceptibility to renal dysfunction. Food Chem Toxicol 2004;42:2053–2060.

54.Lee IC, Ko JW, Park SH, et al. Comparative toxicity and biodis-tribution of copper nanoparticles and cupric ions in rats. Int J Nanomedicine 2016;11:2883–2900.

55.Szyman´ ski P, Fra˛czek T, Markowicz M, Mikiciuk-Olasik E. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals 2012;25:1089–1112.

56.Saghiri MA, Asatourian A, Orangi J, Sorenson CM, Sheibani N. Functional role of inorganic trace elements in angiogenesis—Part II: Cr, Si, Zn, Cu, and S. Crit Rev Oncol Hematol 2015;96:143–155.

57.Patil SA, Patil SA, Patil R, et al. N-heterocyclic carbene metal complexes as bio-organometallic antimicrobial and anticancer drugs. Future Med Chem 2015;7:1305–1333.

58.Kalinowski DS, Stefani C, Toyokuni S, et al. Redox cycling met-als: Pedaling their roles in metabolism and their use in the de-velopment of novel therapeutics. Biochim Biophys Acta 2016; 1863:727–748.

59.Zhou M, Tian M, Li C. Copper-based nanomaterials for cancer imaging and therapy. Bioconjug Chem 2016;27:1188–1199.

60.Siczek K, Zatorski H, Fichna J. Silver and other metals in the treatment of gastrointestinal diseases. Curr Med Chem 2015; 22:3695–3706.

61.Kornblatt AP, Nicoletti VG, Travaglia A. The neglected role of copper ions in wound healing. J Inorg Biochem 2016;161:1–8.